GSK becomes first big pharma to seek gene therapy approval
This article was originally published in SRA
Britain's biggest drug maker, GlaxoSmithKline, is seeking regulatory approval in Europe to use gene transfer technology in children born with ADA-SCID and has further programs using the approach in two other rare diseases, metachromatic leukodystrophy and Wiskott-Aldrich syndrome, with both currently in clinical trials1.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.